U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H19N3O3S
Molecular Weight 345.416
Optical Activity ( - )
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ESOMEPRAZOLE

SMILES

COC1=CC2=C(NC(=N2)[S@@+]([O-])CC3=NC=C(C)C(OC)=C3C)C=C1

InChI

InChIKey=SUBDBMMJDZJVOS-DEOSSOPVSA-N
InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)/t24-/m0/s1

HIDE SMILES / InChI

Molecular Formula C17H19N3O3S
Molecular Weight 345.416
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Esomeprazole strontium is a proton pump inhibitor. It suppresses gastric acid secretion by specific inhibition H+/K+ ATPase in the gastric parietal cell. The S- and R-isomers of omeprazole are protonated and converted in the acidic compartment of the parietal cell forming the active inhibitor, the achiral sulphenamide. By acting specifically on the proton pump, esomeprazole blocks the final step in acid production, thus reducing gastric acidity. The drug is indicated for the treatment of gastroesophageal reflux disease, reduction the risk of NSAID-associated gastric ulcer, eradication of H.pylori, and pathological hypersecretory conditions.

CNS Activity

Curator's Comment: Known to be CNS penetrant in mouse. Human data not available

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
NEXIUM 24HR

Approved Use

treats frequent heartburn (occurs 2 or more days a week)

Launch Date

2014
Primary
PRILOSEC

Approved Use

PRILOSEC is a proton pump inhibitor indicated for: treatment of duodenal ulcer in adults, treatment of gastric ulcer in adults. Treatment of Gastroesophageal Reflux Disease. Maintenance of healing of erosive esophagitis in pediatric patients and adults. Treatment of pathological hypersecretory conditions in adults.

Launch Date

2008
Primary
PRILOSEC

Approved Use

PRILOSEC is a proton pump inhibitor indicated for: treatment of duodenal ulcer in adults, treatment of gastric ulcer in adults. Treatment of Gastroesophageal Reflux Disease. Maintenance of healing of erosive esophagitis in pediatric patients and adults. Treatment of pathological hypersecretory conditions in adults.

Launch Date

2008
Primary
PRILOSEC

Approved Use

PRILOSEC is a proton pump inhibitor indicated for: treatment of duodenal ulcer in adults, treatment of gastric ulcer in adults. Treatment of Gastroesophageal Reflux Disease. Maintenance of healing of erosive esophagitis in pediatric patients and adults. Treatment of pathological hypersecretory conditions in adults.

Launch Date

1989
Primary
PRILOSEC

Approved Use

PRILOSEC is a proton pump inhibitor indicated for: treatment of duodenal ulcer in adults, treatment of gastric ulcer in adults. Treatment of Gastroesophageal Reflux Disease. Maintenance of healing of erosive esophagitis in pediatric patients and adults. Treatment of pathological hypersecretory conditions in adults.

Launch Date

2008
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
668 ng/mL
1 mg/kg single, oral
dose: 1 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
OMEPRAZOLE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7.5 μM
40 mg 1 times / day multiple, intravenous
dose: 40 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ESOMEPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1200 nM*h
20 mg single, oral
dose: 20 mg
route of administration: oral
experiment type: single
co-administered:
OMEPRAZOLE plasma
Homo sapiens
population: healthy
age: adults
sex:
food status:
1220 ng × h/mL
1 mg/kg single, oral
dose: 1 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
OMEPRAZOLE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1179 nM × h
20 mg 1 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OMEPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
16.2 μM × h
40 mg 1 times / day multiple, intravenous
dose: 40 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ESOMEPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.58 h
20 mg 1 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OMEPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.4 h
40 mg 1 times / day multiple, intravenous
dose: 40 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ESOMEPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, 45.2
Health Status: unhealthy
Age Group: 45.2
Sex: M+F
Sources:
Other AEs: Nausea, Diarrhoea...
Other AEs:
Nausea (7%)
Diarrhoea (6%)
Headache (3%)
Sources:
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Other AEs: Headache, Abdominal pain...
Other AEs:
Headache (6.9%)
Abdominal pain (5.2%)
Nausea (4%)
Diarrhea (3.7%)
Vomiting (3.2%)
Flatulence (2.7%)
Esophageal acid reflux (1.9%)
Upper respiratory infection (1.9%)
Constipation (1.5%)
Dizziness (1.5%)
Rash (1.5%)
Asthenia (1.3%)
Back pain (1.1%)
Cough (1.1%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Headache 3%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, 45.2
Health Status: unhealthy
Age Group: 45.2
Sex: M+F
Sources:
Diarrhoea 6%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, 45.2
Health Status: unhealthy
Age Group: 45.2
Sex: M+F
Sources:
Nausea 7%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, 45.2
Health Status: unhealthy
Age Group: 45.2
Sex: M+F
Sources:
Back pain 1.1%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Cough 1.1%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Asthenia 1.3%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Constipation 1.5%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Dizziness 1.5%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Rash 1.5%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Esophageal acid reflux 1.9%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Upper respiratory infection 1.9%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Flatulence 2.7%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Vomiting 3.2%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Diarrhea 3.7%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Nausea 4%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Abdominal pain 5.2%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Headache 6.9%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
strong [IC50 3.7 uM]
yes (co-administration study)
Comment: Esomeprazole administration resulted in a significant increase (1.67‐fold) in the AUC0–∞ of proguanil and a significant decrease (0.522‐fold) in that of cycloguanil
weak [IC50 >40 uM]
weak [IC50 >40 uM]
weak [IC50 >40 uM]
weak [IC50 >40 uM]
weak [IC50 >40 uM]
weak [IC50 >40 uM]
weak [Ki 150 uM]
weak (co-administration study)
Comment: Omeprazole exerts a concentration-dependent inhibition of CYP1A2 activity in man. However, even after single oral doses up to 80 mg, this effect is weak and without clinical relevance
weak [Ki 367.5 uM]
weak [Ki 745.1 uM]
yes [IC50 1.2 uM]
likely (co-administration study)
Comment: The frequency of delayed MTX elimination in patients administered esomeprazole was 71.4%
yes [IC50 15.7 uM]
yes [IC50 17.6 uM]
yes [IC50 17.7 uM]
yes [IC50 22 uM]
yes [IC50 4.32 uM]
yes [IC50 6.7 uM]
yes [IC50 6.8 uM]
yes [IC50 84.3 uM]
unlikely (co-administration study)
Comment: Coaministration with simvastatin acid unlikely results in DDIs
yes [Ki 7.1 uM]
yes (co-administration study)
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes (expression study)
Comment: livers of patients treated with omeprazole showed higher MRP3 protein expression
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: When voriconazole was given with omeprazole to healthy subjects, it significantly increased the steady-state Cmax and AUC0-24 of omeprazole, an average of 2 times and 4 times, respectively
major
yes (co-administration study)
Comment: Drugs known to induce CYP2C19 or CYP3A4 (such as rifampin) may lead to decreased omeprazole serum levels. In a cross-over study in 12 healthy male subjects, St John’s wort, an inducer of CYP3A4, decreased the systemic exposure of omeprazole in CYP2C19 poor metabolisers (Cmax and AUC decreased by 37.5% and 37.9%, respectively) and extensive metabolisers (Cmax and AUC decreased by 49.6% and 43.9%, respectively)
minor
minor
minor
no
yes
yes (co-administration study)
Comment: Drugs which induce CYP2C19 or CYP3A4 (such as St. John’s Wort or rifampin) can substantially decrease esomeprazole concentrations
yes
yes (pharmacogenomic study)
Comment: Drugs which induce CYP2C19 or CYP3A4 (such as St. John’s Wort or rifampin) can substantially decrease esomeprazole concentrations; The CYP2C19 isoenzyme exhibits polymorphism in the metabolism of esomeprazole, since some 3% of Caucasians and 15–20% of Asians lack CYP2C19 and are termed poor metabolizers. At steady state, the ratio of AUC in poor metabolizers to AUC in the rest of the population (normal metabolizers) is approximately 2
PubMed

PubMed

TitleDatePubMed
The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies.
2000 Oct
Differentiation between reinfection and recrudescence of helicobacter pylori strains using PCR-based restriction fragment length polymorphism analysis.
2001 Feb
Recurrent ulcer bleeding: is intravenous omeprazole the solution?
2001 Feb
CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam.
2001 Feb
Leishmania plasma membrane Mg2+-ATPase is a H+/K+-antiporter involved in glucose symport. Studies with sealed ghosts and vesicles of opposite polarity.
2001 Feb 23
Upper gastrointestinal bleeding as a metastatic manifestation of breast cancer: a case report and review of the literature.
2001 Jan
Accuracy of the stool antigen test in the diagnosis of Helicobacter pylori infection before treatment and in patients on omeprazole therapy.
2001 Jan
The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication.
2001 Mar
Electrochemical studies and differential pulse polarographic analysis of lansoprazole in pharmaceuticals.
2001 Mar
Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice.
2001 Mar 9
Patents

Sample Use Guides

Active Duodenal Ulcer: 20 mg Once daily for 4 weeks. Some patients may require an addition 4 weeks. Gastric Ulcer: oral dose is 40 mg once daily for 4-8 weeks. Gastroesophageal Reflux Disease: The recommended adult oral dose for the treatment of patients with symptomatic GERD and no esophageal lesions is 20 mg daily for up to 4 weeks. The recommended adult oral dose for the treatment of patients with erosive esophagitis and accompanying symptoms due to GERD is 20 mg daily for 4 to 8 weeks.
Route of Administration: Oral
Pretreatment of omeprazole (10-6 - 10-4M) dose-dependently inhibits neutrophil adherence and respiratory burst induced by H. pylori. These evidences imply that omeprazole may exhibit a beneficial effect on H. pylori-associated gastric mucosal damage caused by activated neutrophils.
Substance Class Chemical
Created
by admin
on Wed Apr 02 09:33:02 GMT 2025
Edited
by admin
on Wed Apr 02 09:33:02 GMT 2025
Record UNII
N3PA6559FT
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ESOMEPRAZOLE
INN   MART.   VANDF   WHO-DD  
INN  
Official Name English
INEXIUM PARANOVA
Preferred Name English
H199/18
Common Name English
A02BC05
Code English
OMEPRAZOLE S-FORM [MI]
Common Name English
ESOMEPRAZOLE [VANDF]
Common Name English
1H-BENZIMIDAZOLE, 5-METHOXY-2-((S)-((4-METHOXY-3,5-DIMETHYL-2-PYRIDINYL)METHYL)SULFINYL)-
Systematic Name English
Esomeprazole [WHO-DD]
Common Name English
esomeprazole [INN]
Common Name English
5-METHOXY-2-((S)-((4-METHOXY-3,5-DIMETHYL-2-PYRIDYL)METHYL)SULFINYL)BENZIMIDAZOLE
Systematic Name English
ESOMEPRAZOLE [MART.]
Common Name English
OMEPRAZOLE S-FORM
MI  
Common Name English
OMEPRAZOLE, (S)-
Common Name English
Classification Tree Code System Code
WHO-VATC QB01AC56
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
WHO-ATC B01AC56
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
WHO-ATC A02BC05
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
NDF-RT N0000175525
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
WHO-VATC QM01AE52
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
WHO-ATC A02BD06
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
LIVERTOX 370
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
WHO-ATC M01AE52
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
NDF-RT N0000000147
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
WHO-VATC QA02BC05
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
NCI_THESAURUS C29723
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
FDA ORPHAN DRUG 684119
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
WHO-VATC QA02BD06
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
EMA ASSESSMENT REPORTS NEXIUM CONTROL (AUTHOIRIZED: GASTROESOPHAGEAL REFLUX)
Code System Code Type Description
MERCK INDEX
m8209
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
PRIMARY Merck Index
IUPHAR
5488
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
PRIMARY
HSDB
8158
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
PRIMARY
DRUG CENTRAL
1055
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
PRIMARY
NDF-RT
N0000182140
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
PRIMARY Cytochrome P450 2C19 Inhibitors [MoA]
DAILYMED
N3PA6559FT
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
PRIMARY
ChEMBL
CHEMBL1201320
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
PRIMARY
PUBCHEM
9568614
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
PRIMARY
RXCUI
283742
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
PRIMARY RxNorm
DRUG BANK
DB00736
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
PRIMARY
SMS_ID
100000087252
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
PRIMARY
WIKIPEDIA
ESOMEPRAZOLE
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
PRIMARY
EVMPD
SUB01960MIG
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
PRIMARY
EPA CompTox
DTXSID4044292
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
PRIMARY
LACTMED
Esomeprazole
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
PRIMARY
INN
7766
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
PRIMARY
CHEBI
50275
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
PRIMARY
NCI_THESAURUS
C65538
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
PRIMARY
CAS
119141-88-7
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
PRIMARY
FDA UNII
N3PA6559FT
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
PRIMARY
MESH
D064098
Created by admin on Wed Apr 02 09:33:02 GMT 2025 , Edited by admin on Wed Apr 02 09:33:02 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
METABOLITE INACTIVE -> PARENT
METABOLITE INACTIVE -> PARENT
MAJOR
METABOLITE INACTIVE -> PARENT
Metabolism of esomeprazole occurs via the hepatic CYP isoforms CYP2C19 and CYP3A4, which produce the 2 main pharmacologically inactive hydroxy and sulphone metabolites, respectively
MAJOR
METABOLITE ACTIVE -> PRODRUG
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC PEDIATRICS
PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC CHILDREN

ORAL BIOAVAILABILITY PHARMACOKINETIC